Advertisement

PharmacoEconomics

, Volume 12, Issue 3, pp 374–383 | Cite as

Cost-Effective Treatment of Uncomplicated Gonorrhoea Including Co-Infection with Chlamydia trachomatis

  • Mehmet GençEmail author
  • Per-Anders Mårdh
Original Research Article

Summary

We evaluated the cost effectiveness of treating uncomplicated gonorrhoea in a theoretical cohort of 1000 adults (nonpregnant women of reproductive age, or men) with either intramuscular ceftriaxone 125mg or a single oral dose of cefixime 400mg, ofloxacin 400mg or ciprofloxacin 500mg. We assumed that all patients were also empirically treated for uncomplicated chlamydial infection, with either a single oral dose of azithromycin 1g, or oral doxycycline 100mg twice daily for 7 days.

Treatment of gonorrhoea with intramuscular ceftriaxone was found to be the most cost-effective alternative. This was followed by treatment with the either of the fluoroquinolones (ofloxacin or ciprofloxacin), then cefixime.

For empirical treatment of uncomplicated chlamydial infection, doxycycline was more cost effective than azithromycin when approximately more than 80% of the patients were assumed to comply with the doxycycline regimen. When patients’ compliance was poor with the doxycycline regimen, the azithromycin therapy became more cost effective from a societal viewpoint. Nevertheless, its relatively high cost to the individual patient with limited financial resources might prevent him or her from filling prescriptions. Any decrease in patients’ compliance with the azithromycin therapy would favour treatment with doxycycline.

Keywords

Ceftriaxone Doxycycline Azithromycin Chlamydia Trachomatis Pelvic Inflammatory Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moran J, Levine W. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl.: S47–65PubMedCrossRefGoogle Scholar
  2. 2.
    Magid D, Douglas J, Schwartz J. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Ann Intern Med 1996; 124: 389–99PubMedGoogle Scholar
  3. 3.
    Weber JT, Johnson RE. New treatments for Chlamydia trachomatis genital infection. Clin Infect Dis 1995; 20 Suppl.: S66–71PubMedCrossRefGoogle Scholar
  4. 4.
    Genç M, Ruusuvaara L, Mårdh P-A. An economic evaluation of screening for Chlamydia trachomatis in adolescent males. JAMA 1993; 270: 2057–64PubMedCrossRefGoogle Scholar
  5. 5.
    Haddix AC, Hillis SD, Kassler WJ. The cost-effectiveness of azithromycin for Chlamydia trachomatis infections in women. Sex Transm Dis 1995; 22: 274–80PubMedCrossRefGoogle Scholar
  6. 6.
    Genç M, Mårdh P-A. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann Intern Med 1996; 124: 1–7PubMedGoogle Scholar
  7. 7.
    Nettleman MD, Jones RB. Cost-effectiveness of screening women at moderate risk for genital infections caused by Chlamydia trachomatis. JAMA 1988; 260: 207–13PubMedCrossRefGoogle Scholar
  8. 8.
    Stamm WE, Hicks CB, Martin DH, et al. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men: a randomized double-blind study. JAMA 1995; 274: 545–9PubMedCrossRefGoogle Scholar
  9. 9.
    Holmes KK. Screening and the detection of gonorrhea. West J Med 1975; 123: 367–71PubMedGoogle Scholar
  10. 10.
    Phillips RS, Safran C, Aronson MD, et al. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal. Am J Med 1989; 86: 297–302PubMedCrossRefGoogle Scholar
  11. 11.
    Pappius EM, Komaroff AL, Vosseler MG, et al. Gonorrhea case-finding among asymptomatic men seeking ambulatory care: a cost-effectiveness analysis. Sex Transm Dis 1984; 11: 123–30PubMedCrossRefGoogle Scholar
  12. 12.
    Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industralized countries. Am J Obstet Gynecol 1980; 138: 880–92PubMedGoogle Scholar
  13. 13.
    Gutman L, Wilfert CM. Gonococcal diseases in infants and children. In: Holmes K, Mårdh P-A, Sparling P, et al., editors. Sexually transmitted diseases. New York: McGraw Hill, Inc., 1990: 803–10Google Scholar
  14. 14.
    Hook EW, Roody RR, Hansfield HH. Ceftriaxone therapy for incubating and early syphilis. J Infect Dis 1988; 158: 881–4PubMedCrossRefGoogle Scholar
  15. 15.
    Nettleman M, Smith V, Moyer N. Penicillin resistant Neisseria gonorrhoeae in low prevalence areas: implications for cost-effective management. Sex Transm Dis 1990; 17: 175–80PubMedCrossRefGoogle Scholar
  16. 16.
    Friedland L, Kulick M, Biro F, et al. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis. Ann Emerg Med 1996; 27: 299–304PubMedCrossRefGoogle Scholar
  17. 17.
    WHO Advisory Group on Sexually Transmitted Diseases Treatments. Recommendations of the management of sexually transmitted diseases. Report of a WHO advisory group meeting on sexually transmitted diseases treatments; 1993 Feb 18–19. Report no: WHO/GPA/STD/93.1. Geneva: World Health Organization, 1993Google Scholar
  18. 18.
    Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR CDC Surveill Summ 1993; 42(RR-14): 56–60Google Scholar
  19. 19.
    Katz B, Zwickl B, Caine V, et al. Compliance with antibiotic treatment for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Transm Dis 1992; 19: 351–4PubMedCrossRefGoogle Scholar
  20. 20.
    Blonna R, Legos P, Burlack P. The effects of an STD educational intervention on follow-up appointment keeping and medication taking. Sex Transm Dis 1989; 16: 198–200PubMedCrossRefGoogle Scholar
  21. 21.
    Katz B, Caine V, Battaiger B, et al. A randomized trial to compare 7- and 21-day tetracycline regimens in the prevention of recurrence of infection with Chlamydia trachomatis. Sex Transm Dis 1991; 18: 36–40PubMedCrossRefGoogle Scholar
  22. 22.
    Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984; 100: 258–68PubMedGoogle Scholar
  23. 23.
    Para W, Drotman D, Siegel K, et al. Patient counselling and behavioral modification. In: Holmes K, Mårdh P-A, Sparling P, et al., editors. Sexually transmitted diseases. New York: McGraw Hill, Inc., 1990: 1057–68Google Scholar
  24. 24.
    Lode H, Borner K, Koeppe P, et al. Azithromycin: review of key chamical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37 Suppl. C: 1–8PubMedCrossRefGoogle Scholar
  25. 25.
    Brown S, Pedersen A, Holmes K. Comparison of erythromycin base and estolate in gonococcal urethritis. JAMA 1977; 238: 1371–3PubMedCrossRefGoogle Scholar
  26. 26.
    Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care for pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Department of MedicineMarmara University Faculty of MedicineIstanbulTurkey
  2. 2.Uppsala University Center for STD Research, Institute of Clinical BacteriologyUppsala UniversityUppsalaSweden

Personalised recommendations